What are the precautions for mabelantuzumab?

Berantuzumab is an innovative drug for the treatment of relapsed or refractory multiple myeloma. It is suitable for adult patients who have received at least four treatments (including anti-CD38 monoclonal antibodies, proteasome inhibitors and immunomodulators) but whose disease has not been effectively controlled. However, before using belantuzumab, patients need to fully understand and follow a series of important precautions to ensure the safety and effectiveness of the treatment.

Before receiving treatment with belantuzumab, patients must inform their health care provider of all their medical conditions. This is especially true for patients with a history of vision or eye problems, as belantuzumab may cause ocular adverse reactions such as corneal lesions. At the same time, patients with bleeding problems or a history of bleeding problems should also use it with caution to avoid possible bleeding risks. Belantuzumab is contraindicated in women who are pregnant or planning to become pregnant because of the potential for harm to the fetus.

Therefore, women who are able to become pregnant should take a pregnancy test before starting treatment and use effective contraception during treatment and for 4 months after the last dose. Likewise, men with a female partner who is capable of pregnancy should use contraception during treatment and for 6 months after the last dose. Additionally, lactating women should avoid breastfeeding because it is not known whether this drug passes into breast milk. For patients who are concerned about their fertility, it is recommended to consult a healthcare provider for more information.

In addition, patients should inform their healthcare provider of all medications they take during treatment, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements, to avoid potential drug interactions.

During treatment, if a patient develops serious side effects, medical staff may reduce the dose, temporarily stop or completely discontinue berantuzumab treatment depending on the specific situation. Therefore, patients should pay close attention to their body's reactions and communicate with medical staff in a timely manner.

In short, belantuzumab is an effective treatment for multiple myeloma, but patients need to fully understand and follow relevant precautions before and during use to ensure that the treatment is safe and effective. At the same time, close communication and cooperation with medical staff are the key to successful treatment.

Reference materials:https://www.drugs.com/search.php?searchterm=Blenrep&sources%5B%5D=professional